Jane Lian to Tumor Microenvironment
This is a "connection" page, showing publications Jane Lian has written about Tumor Microenvironment.
Connection Strength
0.279
-
Gordon JA, Lisle JW, Alman BA, Lian JB. Disruption of crosstalk between mesenchymal stromal and tumor cells in bone marrow as a therapeutic target to prevent metastatic bone disease. J Cell Physiol. 2014 Dec; 229(12):1884-6.
Score: 0.111
-
Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, Li X, Bedard K, Dhillon RJ, van Wijnen AJ, Stein JL, Stein GS, Westendorf JJ, Lian JB. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther. 2010 Dec; 9(12):3210-20.
Score: 0.084
-
Fritz AJ, Hong D, Boyd J, Kost J, Finstaad KH, Fitzgerald MP, Hanna S, Abuarqoub AH, Malik M, Bushweller J, Tye C, Ghule P, Gordon J, Frietze S, Zaidi SK, Lian JB, Stein JL, Stein GS. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. J Cell Physiol. 2020 10; 235(10):7261-7272.
Score: 0.040
-
Zaidi SK, Trombly DJ, Dowdy CR, Lian JB, Stein JL, van Wijnen AJ, Stein GS. Epigenetic mechanisms in leukemia. Adv Biol Regul. 2012 Sep; 52(3):369-76.
Score: 0.023
-
Pratap J, Lian JB, Stein GS. Metastatic bone disease: role of transcription factors and future targets. Bone. 2011 Jan; 48(1):30-6.
Score: 0.020